The globalization of risk and risk perception: why we need a new model of risk communication for vaccines. by Larson, Heidi et al.
Larson, H; Brocard Paterson, P; Erondu, N (2012) The globalization
of risk and risk perception: why we need a new model of risk com-
munication for vaccines. Drug safety, 35 (11). pp. 1053-9. ISSN
0114-5916 DOI: https://doi.org/10.2165/11635880-000000000-00000
Downloaded from: http://researchonline.lshtm.ac.uk/354885/
DOI: 10.2165/11635880-000000000-00000
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
 drs 1163588 2012 00 00 000 000 DR01163588 10.2165/11635880-000000000-00000 
Review Article 
Larson et al. 
Globalization of Risk Perception of Vaccines((Author: please confirm/amend)) 
The Globalization of Risk and Risk Perception 
Why We Need a New Model of Risk Communication for Vaccines 
Heidi Larson, Pauline Brocard Paterson and Ngozi Erondu 
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, Keppel Street, London WC1E 7HT, UK 
Correspondence: Dr Heidi Larson,((Author: please confirm Dr is your correct title)) 
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, Keppel Street, London WC1E 7HT, UK.  
E-mail: Heidi.larson@lshtm.ac.uk((Author: please confirm that you are happy for us to 
publish your e-mail address)) 
Abstract 
Risk communication and vaccines is complex and the nature of risk perception is changing, 
with perceptions converging, evolving, and having impacts well beyond specific geographic 
localities and points in time, especially when amplified through the iInternet and other modes of 
global communication. 
This article examines the globalization of risk perceptions and their impacts, including the 
example of measles and the globalization of measles, mumps and rubella (MMR) vaccine risk 
perceptions, and calls for a new, more holistic model of risk assessment, risk communication and 
risk mitigation, embedded in an ongoing process of risk management for vaccines and 
immunization programmes. It envisions risk communications as an ongoing process that 
includes trust-building strategies hand-in-hand with operational and policy strategies needed to 
mitigate and manage vaccine-related risks, as well as perceptions of risk. 
 
Keywords: Human-papillomavirus-vaccine; Measles-mumps-and-rubella-virus-vaccine; Risk-management; 
Vaccines.((Author: these keywords are for our internal use only and can be ignored)) 
 
 
<ARTICLE.PART> 
 
 ((Author: If you add a reference to this article, please add it to the end of your current 
reference list - our system will automatically renumber the reference citations so that they 
are sequential prior to page proofs being created)) 
 
1. Introduction 
The need for effective vaccine risk communication is well- established,,[1-4] and is becoming 
increasingly important in light of the growing global diversity of vaccines and vaccine 
schedules, compounded by a more complex communication environment and growing pockets 
of vaccine hesitancy around the world. 
We live in a time of short attention spans and eagerness for ‘quick fix’ solutions, without often 
thinking of the longer-term implications of our actions. Parents are making decisions, sometimes 
driven by short-term vaccine scares, for children who have no choice or voice and who may 
become seriously ill with easily preventable diseases later in life because of not being vaccinated 
as a child. 
It is difficult to talk about risk communication outside of the context of a broader continuum of 
ongoing risk management, which includes risk assessment and understanding of risk 
perceptions, which can vary widely depending on historic experiences as well as socio-
economic, cultural,[5-7] and political contexts.,[8,9] Comprehensive risk prevention and 
management plans are needed which include strong risk communication components, and which 
consider risks to individuals, risks to society, and risks to immunization programmes.  
While there are systems in place for vaccine safety vigilance around the world, albeit some 
more robust than others, there are few systems in place which that monitor not only specific 
vaccine safety concerns, but also other public concerns about vaccines and immunization 
programmes which that can pose equal risks to vaccination programmes if not heard and 
addressed. 
 
2.1. What Do We Mean by ‘“Risk’”? 
In 2002, the World Health OrganizationWHO’s annual World Health Report chose the theme 
of “reducing risks, promoting healthy life” and defined risk as “a probability of an adverse 
outcome, or a factor that raises this probability”. The 2002 report emphasizes the importance of 
recognizing the socio-cultural and economic factors that affect people’s risk perceptions as well 
as the importance of considering these factors when designing risk management policies.[10] 
Some of the best work on risk perception and risk communication has evolved in the 
environmental sciences in response to citizen debates around nuclear energy plants and other 
technologies that had high perceived risks among some citizen groups. Peter Sandman, 
renowned risk communication expert, developed a now classic formula for risk communication: 
Risk = Hazard + Outrage, recognizing that there are various factors that influence outrage as 
well as perception of hazard.,[11,12]  
In the vaccine field, the focus on risk communication is often specific to vaccine safety and on 
communicating the benefits of vaccines as well as being transparent about the potential risks of 
an adverse event following immunization (AEFI)((Author: abbreviation not used again. Ok 
to delete?)). More attention is needed on communicating the potential risks to societies as well 
as reputational risks to immunization programmes of unmanaged risk perceptions and vaccine 
anxieties left unaddressed. 
Furthermore, it is important to take into account the multiple dimensions of risk. Risk expert 
Paul Slovic talks about different aspects of risk. He characterizes three types of risk: “Risk as 
feelings refers to our fast, instinctive, and intuitive feelings to danger. Risk as analysis brings 
logic, reason, and scientific deliberation to bear on hazard management ... and the third reality, 
risk as politics.”[13] 
In addressing risk communication around vaccines, ‘“risk as analysis’” is often the primary 
mode of risk which that is considered, with only recently emerging attention paid to the equally 
important domains of ‘“risk as feelings’” and ‘“risk as politics’”. The emerging shift in the 
public health community to increasingly acknowledge the broader realms of ‘“risk as feelings’” 
and ‘“as politics’” is largely in response to having been faced with an epidemic of crises in 
public confidence in vaccines. These include persisting concerns around the measles, mumps, 
and rubella (MMR) vaccine despite ample evidence refuting suspected links between the MMR 
vaccine and autism; and outright anti-vaccination movements which that have been driven by 
‘“risk as feelings’” or ‘“risk as politics’”, which have led to behavioural outcomes such as 
delaying or refusing vaccines. An example is the 2003–2004 state-wide boycotts of the oral 
polio vaccination in five states in northern Nigeria, which were, in large part, driven by 
politics.,[14,15]  
While northern Nigeria boycotted the oral polio vaccine (OPV) vaccine((Author: ok?)), 
similar fears of OPV causing sterilization were circulating in India.[16] ButHowever, in the case 
of India, there were other underlying programmatic concerns which that were driving the 
anxieties. Even though the expressed concern was that the oral polio vaccineOPV caused 
sterilization (because that was what others in the community were saying), local research 
revealed that the real anxiety among some was that they preferred that their children were 
vaccinated by a woman, rather than a man, and that the vaccinator was from the local 
community and not from a distant area. The exercise of even engaging in dialogue was a trust-
building gesture, and the adapting of the vaccine delivery mode to accommodate the local 
preferences contributed to a decrease in vaccine anxieties and increased the take-up of the 
vaccine, in a situation where more communication targeted to the community about the safety of 
the vaccine would not have alleviated the concerns. 
Without sitting down with those who are anxious about vaccines and discussing more 
explicitly why they are afraid of a particular vaccine and what might alleviate their fears, the 
appropriate risk management intervention would not have been known and ‘“more of the same’” 
communication on the benefits of the vaccine might have only aggravated popular anxieties.  
In another example, the 2010 suspension of the human papillomavirus (HPV)((Author: ok?)) 
vaccine demonstration project in India[17] illustrates that there can be multiple levels of risk 
perception, in multiple locations, that may have their impact in a geographic location different 
from the source of the amplified risk perception. In the HPV vaccine project in India, different 
modes of vaccine delivery were being compared in two states (Gujarat and Andhra Pradesh) 
where there had been ample community engagement before and during the project’s 
implementation, and acceptance levels of the vaccine in both states were high. The risk 
perceptions and activism that ultimately led to the suspension of the project one 1 year before its 
completion came from outside the local areas where the project was being carried out, and 
instead were driven by a member of parliament from the Communist Party of India, coming 
from West Bengal, along with a women’s group in Delhi, and supported by an anti-HPV 
vaccination group in the United StatesUS called truthaboutguardasil.org.  
Another example of spatially diverse risk perceptions were the concerns and anti-vaccination 
movements in the 1970s which questioned the safety and relevance of the pertussis vaccine,[18] 
and led to increases in pertussis cases in several countries, including Sweden, Japan, the UK, the 
Russian Federation, Ireland, Italy and Australia. The anti-vaccine sentiments included those of 
paediatricians and virologists who questioned the continued need for the vaccine – relative to its 
risks – despite the fact that its use had significantly reduced the incidence of pertussis following 
its successful introduction in the 1950s. 
Two decades after the multi-country pertussis vaccine concerns and the consequent disease 
outbreaks, a new crisis of confidence emerged – and globalized – around the MMR vaccine.  
 
3.2. The Globalization of Risk Perception: The Example of Measles 
The year 2013 will mark 50 years since the first measles vaccine was licencsed. Despite the 
widespread use and demonstrated efficacy of the measles vaccine since its first 1963 licensure, 
there were 34 250 confirmed cases of measles across the WHO European Rregion1 alone in 
2011.[19]  
Measles outbreaks due to under-vaccination also occurred in Ukraine, Russia and the UK in 
2012, and there were a high number of cases in the US, Canada, Australia, New Zealand, Kenya, 
Somalia, India and Mozambique.[20] The reasons are varied, but in a number of these countries 
infrastructure is not the primary barrier to vaccine coverage. Instead, a combination of 
perceptions of low risk around measles disease and perceptions of the vaccine being high risk 
has converged to create gaps in vaccine coverage, gaps in herd immunity and consequent disease 
outbreaks. In some cases, adverse events have given genuine cause for concern, such as around 
the Urabe mumps strains used in some of the MMR vaccines in the 1990s and, in other cases, 
new research which has prompted public concerns and debate, such as around the purported 
links between MMR and autism. leading to what Seth Mnookin[52] calls the ‘panic virus’. 
 
In 1992, four 4 years after the MMR vaccine was introduced in the UK, the Department of 
Health withdrew MMR vaccines containing the Urabe strain of the mumps virus after an 
association with an increased risk of aseptic meningitis was found.[21] Canada, Japan and Brazil 
also suspended the same type of MMR vaccine as evidence emerged of safety risks. Although 
there was no initial decline in the MMR (without the Urabe strain) vaccine coverage in the UK, 
the episode contributed to fertile ground for public questioning.[22,23]  
Acceptance of the MMR vaccine in the UK reached a high of nearly 92% for children under 
the age of 2 years two in 1994–1995.[24] ButHowever, in the decade that followed, a barrage of 
questions and concerns contributed to a steady 10-year decline in vaccine coverage, the lowest 
being at a dangerously low 79% in 2003–2004,[25] following the widely publicized claims 
propagated by Andrew Wakefield that there were links between the MMR vaccine, bowel 
disease and autism.[26] Although the links have been widely scientifically refuted,[27-29] and MMR 
vaccine coverage rates have improved, some concerns persist in the UK. Additionally, purported 
links between the vaccine preservative thimerosal and autism have fuelled other vaccine 
anxieties,[30-32] initially in the USA, but becoming more global.  
Today the UK claims an MMR coverage rate of 89.1% as the National Health Service (NHS) 
and the concerned public continue a more than decade-long battle to restore coverage rates to 
above 90%. ButHowever, in the meanwhile, Andrew Wakefield continues to propagate his 
beliefs,[33] and the MMR vaccine anxieties, along with their consequences of reduced vaccine 
                                                     
1 42 Forty-two Mmember Sstates as defined by the World Health OrganizationWHO. 
uptake and disease outbreaks, have slowly travelled around the world, often merging with other 
underlying historic vaccine concerns.  
Using Peter Sandman’s lens of Risk = Hazard + Outrage, there is a convergence of overly high 
outrage about the risks of the MMR vaccine alongside perceptions of disease hazard which are 
lower than the real hazard which that measles disease warrants.[34-37] An extreme example of 
under-recognition of the potential serious risks of measles is a recent children’s book published 
in Australia titled, Melanie’s Marvellous Measles. As the publisher describes the book on its 
website:  
 “This book takes children aged 4–10 years on a journey of discovering about the 
ineffectiveness of vaccinations, while teaching them to embrace childhood disease, heal if they 
get a disease, and build their immune systems naturally.”[38] 
Globally, the immunization community is facing what a gathering of immunization experts has 
termed “A Crisis of Public Confidence in Vaccines.”.[39] Others have voiced similar concerns.[40] 
The reasons for this crisis span from safety concerns to philosophical and religious beliefs,[41-44] 
and from distrust in governments to theories of political and business motives behind the 
provision of vaccines rather than a sincere intention to prevent disease, such as around the H1N1 
vaccination.  
In the 2009 report to the WHO’s executive board on the state of global measles elimination, 
WHO recognized that infrastructure was not the major barrier to adequate measles vaccine 
coverage in Europe, and concluded that, “Pphilosophical and religious beliefs as well as 
misplaced concerns about vaccine safety are the principle barriers to achieving measles 
elimination.”[45] Country-specific reports throughout the region,[46,47] confirm this.  
Religious and philosophical beliefs and misplaced – as well as some legitimate – concerns 
which are affecting vaccine acceptance are not unique to Europe. In 2011, the United StatesUS 
saw the highest number of measles cases in 15 years. Of the 222 reported cases, 141 were 
unvaccinated even though they were eligible to receive the MMR vaccination. Among the 66 
unvaccinated cases between 16 months and 19 years oldof age, CDC the Centers for Disease 
Control and Prevention reported that 76% were not vaccinated because of ‘“religious, 
philosophical or personal objections’”. And aAmong those cases which that were imported from 
outside the US through travel abroad or through foreign visitors, 46% were from measles disease 
contracted in the WHO European Rregion.[48]  
In other parts of the world, the WHO reports similar concerns in their Aannual Rreport on 
measles progress in the WHO African Rregion, 2009–2010, where they point to religious 
reasons behind non-vaccination in Botswana, Malawi, South Africa and Zimbabwe.[46] 
Concurrent with these local religious and philosophical reasons for non-vaccination is an 
increased global spread of safety concerns. In many cases, multiple types of concerns converge – 
or are corroborated – to substantiate a particular anxiety about a vaccine. South Africa, for 
instance, is seeing the emergence of anti-vaccination groups,[49] including those spreading 
concerns about links between the MMR vaccine and autism, drawing largely from US and UK 
anti-vaccination websites, some of which are also driven by ‘“risk as feelings’” and ‘“risk as 
politics’”. 
 
4.3. Future Directions: A New Model for Vaccine Risk Communication  
Vaccine risk communication is complex as it needs to address not only communicating both 
the risks and benefits of vaccines at the individual level, but also at the societal level, including 
communicating the risks of not vaccinating. It also implies ongoing attentiveness to 
understanding perceptions of risks, as well as mitigating potential risks by ensuring that vaccine 
delivery strategies take into account socio-cultural and political realities which can disrupt 
programmes if they are not planned, and timed, well. Trust-building in immunization 
programmes needs to be an ongoing task.[51] 
We stress the importance of managing perceptions of vaccine-related risks and adverse events 
as being as important as managing scientifically assessed risks and adverse events following 
immunization. Vaccine-related adverse events, as well as perceived, but coincidental, events, 
can both influence a population’s willingness to accept a vaccine.[50] We also urge the expansion 
of risk communication to move beyond a focus on an individual vaccine and its potential risk to 
the individual, to a broader consideration of risks to society and to the functioning of any 
immunization programme, including the potential reputational risks of inadequate risk 
preparedness or badly managed adverse events. Finally, we urge a consideration of more far-
reaching impacts of unmanaged risk perceptions and risk events well beyond specific 
geographical areas, especially when amplified through the iInternet and other modes of global 
communication. 
To capture this expanded framing of vaccine risk communication, below isfigure 1 shows a 
proposed, integrated model where risk communication is embedded in an overall process of risk 
management from risk assessment to inform risk communication with the objective to achieve 
risk mitigation for vaccines and immunization programmes.: 
Fig. 1 
 
5.4. Conclusions 
The nature of risk perception is changing, with multiple translocal and transnational 
perceptions converging, evolving, and having spatial and temporal impacts well beyond specific 
geographic localities and moments of hesitancy or crises in vaccine confidence. 
This paper article introduces a new, more holistic model of risk assessment, risk 
communication and risk mitigation for vaccines and immunization programmes., In this model, 
where risk communication is embedded in an ongoing process that includes communication and 
trust-building strategies hand-in-hand with operational and policy strategies needed to reduce 
risks, as well as perceptions of risk, which can lead to vaccine hesitancy or refusals. Trust-
building in immunization programmes needs to be an ongoing task.[51] 
In order to inform this new approach to risk communication, more research is needed on both 
proximal and distal determinants of vaccine hesitancy and refusals. Furthermore, research needs 
to move beyond surveys and point-in-time research to include longitudinal studies capturing 
influences on vaccine hesitancy and trust in vaccines over time. In particular, research is needed 
which better understands and isolates the “tipping point” influences that move vaccine hesitant 
individuals or groups to becoming vaccine refusers or, alternatively, vaccine advocates. 
We live in a time of short attention spans and eagerness for ‘“quick fix’” solutions, without 
often thinking of the longer-term implications of our actions. Parents are making decisions, 
sometimes driven by short-term vaccine scares, for children who have no choice or voice and 
who may become more seriously ill with easily preventable diseases later in life because of not 
being vaccinated as a child((Author: change ok?)), because of not being vaccinated as a child. 
The recent surge of measles outbreaks are largely among those who have not been vaccinated, 
either because they are too young to be vaccinated, or because they were not vaccinated at the 
recommended age in childhood because of what Seth Mnookin[52] calls the ‘“panic virus’”. 
((Author: please remove references from this section and add to the main text. Please add a 
comment or two on avenues for future research. 
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Fig. 1. Risk Ccommunication re-framed as a component of a risk management process((Author: 
Please confirm whether the last bullet point in the first frame (‘Risk Assessment’) 
should read “Assessment of external risks to vaccine delivery and the 
immunization programme (coinciding events, political scanning, historical events 
that could influence trust)”, as per the original draft?)). 
 
